Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck…
| Price | $2.79 |
|---|---|
| Market cap | $317.62M |
| Sector | Healthcare |
| Industry | Medical - Devices |
| Exchange | AMEX |
| 52-week range | 1.96-6.16 |
| Beta | 1.8 |
Explore CATX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.